Vincerx Pharma

Yahoo Finance • last year

Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2nd cohort Phase 1 dose escalation for VIP236 - first-in-class... Full story

Yahoo Finance • last year

Vincerx Pharma To Present Three Posters at ASH 2023 in December

VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development Enitociclib poster expands potential clinic... Full story

Yahoo Finance • last year

New to The Street Airs Televised Corporate Interviews Episodes 521 and 522 as Sponsored Programming on Bloomberg TV and The Fox Business Network

NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) -- New to The Street, an FMW Media business show production, will air its corporate interviews, episodes 521 and 522, as Sponsored Programming on Bloomberg TV and FOX Business Network. Bloomberg... Full story

Yahoo Finance • last year

New to The Street Announces TV Corporate Appearances, broadcasting Episode 518 on Newsmax and Episode 519 on FOX Business Network, Airings start on Saturday, October 7, 2023, at 3:30 PM ET

NEW YORK, Oct. 06, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces its corporate TV appearances on Newsmax and the FOX Business Network. New to The Street airs Episode 518 on Newsmax on Saturday, October 07, 2023, at 3:... Full story

Yahoo Finance • last year

New to The Street Announces TV Corporate Appearances, Broadcasting Episode 518 on Newsmax and Episode 519 on FOX Business Network, Airings start on Saturday, October 7, 2023, at 3:30 PM ET

NEW YORK, Oct. 06, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces its corporate TV appearances on Newsmax and the FOX Business Network. New to The Street airs Episode 518 on Newsmax on Saturday, October 07, 2023, at 3:... Full story

Yahoo Finance • last year

Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023

PALO ALTO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today anno... Full story

Yahoo Finance • last year

Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943

PALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics,... Full story

Yahoo Finance • last year

Vincerx Pharma Announces FDA Clearance of IND for VIP943

Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx’s development and regulatory expertise PALO ALTO, Ca... Full story

Yahoo Finance • 2 years ago

Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

PALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today pres... Full story

Yahoo Finance • 2 years ago

Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023

PALO ALTO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today pres... Full story

Yahoo Finance • 2 years ago

Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

PALO ALTO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today pres... Full story

Yahoo Finance • 2 years ago

Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an αvβ3 small molecule drug conjugate (SMDC) in advanced solid tumors IND filing for antibody drug conjugate (ADC) VIP943 remains on track for mid-2023; expecte... Full story

Yahoo Finance • 2 years ago

Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023

PALO ALTO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today anno... Full story

Yahoo Finance • 2 years ago

Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today annou... Full story

Yahoo Finance • 2 years ago

Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236

VIP236 is a first-in-class αVβ3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications Preclinical studies with VIP236 demonstrated promising tumor regression in in vivo cance... Full story

Yahoo Finance • 2 years ago

Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types

In a multiple myeloma (MM) preclinical study, antitumor efficacy was observed with enitociclib as a monotherapy and in combination with several anti-MM agents Significant MYC downregulation was observed in patients with double-hit diffuse... Full story

Yahoo Finance • 2 years ago

Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022

Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) when compared with Mylotarg™ (gemtuzuma... Full story

Yahoo Finance • 2 years ago

Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci’s History of Stockholder Value Destruction and Self-Dealing

Diffusion has a highly engaged and independent board that possesses the right skills and experience to execute the strategic review process Diffusion received bids from more than 15 companies participating in review processLifeSci invited... Full story

Yahoo Finance • 2 years ago

Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Received Orphan Drug Designation for enitociclib; continue to focus on priority indications IND submission for first-in-class small molecule drug conjugate (SMDC) VIP236 expected by year-end IND filings for antibody drug conjugates (ADCs... Full story

Yahoo Finance • 2 years ago

Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022

PALO ALTO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today annou... Full story